Finerenone

Finerenone
Clinical data
Trade names	Kerendia
Other names	BAY 94-8862
License data	US DailyMed: Finerenone;
Pregnancy; category	AU: D; ;
Routes of; administration	Oral
Drug class	Potassium-sparing diuretic
ATC code	C03DA05 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only; EU: Rx-only;
Identifiers
	IUPAC name (4S)-4-(4-Cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide;
CAS Number	1050477-31-0;
PubChem CID	60150535;
DrugBank	DB16165;
ChemSpider	28669387;
UNII	DE2O63YV8R;
KEGG	D10633;
ChEMBL	ChEMBL2181927;
CompTox Dashboard (EPA)	DTXSID10146928 ;
ECHA InfoCard	100.247.614
Chemical and physical data
Formula	C21H22N4O3
Molar mass	378.432 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES NC(=O)C1=C(C)Nc2c(C)cnc(OCC)c2[C@@H]1c3ccc(C#N)cc3OC;
	InChI InChI=1S/C21H22N4O3/c1-5-28-21-18-17(14-7-6-13(9-22)8-15(14)27-4)16(20(23)26)12(3)25-19(18)11(2)10-24-21/h6-8,10,17,25H,5H2,1-4H3,(H2,23,26)/t17-/m1/s1; Key:BTBHLEZXCOBLCY-QGZVFWFLSA-N;

Finerenone, sold under the brand name Kerendia and Firialta, is a medication used to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal heart attacks, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes.^[8] Finerenone is a non-steroidal mineralocorticoid receptor antagonist (MRA).^[7] It is taken orally (swallowed by mouth).

Common side effects include hyperkalemia (high levels of potassium), hypotension (low blood pressure), and hyponatremia (low levels of sodium).^[8]

Finerenone was approved for medical use in the United States in July 2021,^[8]^[10] and in the European Union in February 2022.^[9] The U.S. Food and Drug Administration considers it to be a first-in-class medication.^[11]

^ "Updates to the Prescribing Medicines in Pregnancy database". Therapeutic Goods Administration (TGA). 12 May 2022. Retrieved 13 May 2022.
^ ^a ^b "Kerendia APMDS". Therapeutic Goods Administration (TGA). 9 December 2021. Retrieved 12 June 2022.
^ "AusPAR: Finerenone". Therapeutic Goods Administration (TGA). 31 May 2022. Retrieved 12 June 2022.^{[permanent dead link]}
^ "Kerendia Product information". Health Canada. 25 April 2012. Retrieved 2 January 2023.
^ "Kerendia Summary Basis of Decision". Health Canada. 23 October 2014. Retrieved 10 March 2023.^{[permanent dead link]}
^ "Details for: Kerendia". Health Canada. 22 November 2022. Retrieved 3 March 2024.
^ ^a ^b "Kerendia- finerenone tablet, film coated". DailyMed. Retrieved 20 August 2021.
^ ^a ^b ^c ^d "FDA Approves Drug for Chronic Kidney Disease". U.S. Food and Drug Administration (FDA). 9 July 2021. Retrieved 9 July 2021. This article incorporates text from this source, which is in the public domain.
^ ^a ^b "Kerendia EPAR". European Medicines Agency (EMA). 14 December 2021. Retrieved 11 March 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^ "Bayer's Kerendia (finerenone) Receives U.S. FDA Approval for Treatment of Patients with Chronic Kidney Disease Associated with Type 2 Diabetes" (Press release). Bayer. 9 July 2021. Retrieved 9 July 2021 – via Business Wire.
^ Advancing Health Through Innovation: New Drug Therapy Approvals 2021 (PDF). U.S. Food and Drug Administration (FDA) (Report). 13 May 2022. Archived from the original on 6 December 2022. Retrieved 22 January 2023. This article incorporates text from this source, which is in the public domain.

[1] "Updates to the Prescribing Medicines in Pregnancy database". Therapeutic Goods Administration (TGA). 12 May 2022. Retrieved 13 May 2022.

[Kerendia_APMDS-2] "Kerendia APMDS". Therapeutic Goods Administration (TGA). 9 December 2021. Retrieved 12 June 2022.

[3] "AusPAR: Finerenone". Therapeutic Goods Administration (TGA). 31 May 2022. Retrieved 12 June 2022.^{[permanent dead link]}

[4] "Kerendia Product information". Health Canada. 25 April 2012. Retrieved 2 January 2023.

[5] "Kerendia Summary Basis of Decision". Health Canada. 23 October 2014. Retrieved 10 March 2023.^{[permanent dead link]}

[6] "Details for: Kerendia". Health Canada. 22 November 2022. Retrieved 3 March 2024.

[Kerendia_FDA_label-7] "Kerendia- finerenone tablet, film coated". DailyMed. Retrieved 20 August 2021.

[FDA_Kerendia-8] "FDA Approves Drug for Chronic Kidney Disease". U.S. Food and Drug Administration (FDA). 9 July 2021. Retrieved 9 July 2021. This article incorporates text from this source, which is in the public domain.

[Kerendia_EPAR-9] "Kerendia EPAR". European Medicines Agency (EMA). 14 December 2021. Retrieved 11 March 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[10] "Bayer's Kerendia (finerenone) Receives U.S. FDA Approval for Treatment of Patients with Chronic Kidney Disease Associated with Type 2 Diabetes" (Press release). Bayer. 9 July 2021. Retrieved 9 July 2021 – via Business Wire.

[New_Drug_Therapy_Approvals_2021-11] Advancing Health Through Innovation: New Drug Therapy Approvals 2021 (PDF). U.S. Food and Drug Administration (FDA) (Report). 13 May 2022. Archived from the original on 6 December 2022. Retrieved 22 January 2023. This article incorporates text from this source, which is in the public domain.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]